Modular Medical shares surge 52.85% after-hours as validated Pivot controller line advances Q1 2026 insulin pump launch.

Modular Medical surged 52.85% in after-hours trading following the announcement of successful validation of its Pivot controller line, a critical step toward the Q1 2026 commercial launch of its tubeless, removable 3 milliliter patch pump. The validation confirms manufacturing readiness for high-volume production, addressing a $3 billion market for adult "almost-pumpers" with an affordable, user-friendly design. The company emphasized that this milestone reduces commercialization risks and positions it to scale production efficiently, a key differentiator in the insulin pump market. While the Pivot remains uncleared by the FDA, the news signals progress in overcoming manufacturing hurdles and aligns with the company’s strategy to capture market share through scalable, cost-effective solutions. The significant after-hours jump reflects investor optimism about the derisked path to commercialization and potential market expansion.